

(I)

5 R^1 is H, C₁-C₇-alkyl, haloalkyl, cycloalkyl or halocycloalkyl;
 R^2 is H, ~~alkyl, haloalkyl, cycloalkyl or halocycloalkyl~~;
 R^3 is H, ~~alkyl, haloalkyl, cycloalkyl or halocycloalkyl~~;
 R^4 is H, ~~alkyl, haloalkyl, cycloalkyl or halocycloalkyl~~;
 R^5 is H, ~~alkyl, haloalkyl, cycloalkyl or halocycloalkyl~~;
10 R^6 is H, halogen, or C₁-C₇-alkyl, ~~haloalkyl, cycloalkyl or halocycloalkyl~~;
 R^7 is H, ~~halogen, alkyl, haloalkyl, cycloalkyl or halocycloalkyl~~;
 R^8 is H, ~~alkyl, haloalkyl, cycloalkyl or halocycloalkyl~~;
 R^9 is H, ~~alkyl, haloalkyl, cycloalkyl or halocycloalkyl~~;
 R^{10} is H, ~~alkyl, haloalkyl, cycloalkyl or halocycloalkyl~~;
15 R^{11} is H, ~~alkyl, haloalkyl, cycloalkyl or halocycloalkyl~~;
 R^{12} is H, or halogen, ~~alkyl, haloalkyl, cycloalkyl or halocycloalkyl~~;
 A^1 is N ~~or~~ CR¹³;
 A^2 is NR¹⁴ or CR¹⁵R¹⁶;

A³ is N or CR¹⁷;

R¹³ is H, or halogen, alkyl, haloalkyl, cycloalkyl or halocycloalkyl;

R¹⁴ is ~~S(O)₂R¹⁸, S(O)₂OR¹⁸, S(O)₂NR¹⁸R¹⁹, C(O)R¹⁸, C(O)OR¹⁸, C(O)NR¹⁸R¹⁹ or~~
(CR²⁰R²¹)_q-(CR²²R²³)_r-(CR²⁴R²⁵)_p-NR²⁶R²⁷, wherein the sum of q, r and p is at least 2;

5 R¹⁵ is ~~-(CR²⁰R²¹)_q-(CR²²R²³)_r-(CR²⁴R²⁵)_p-NR²⁶R²⁷;~~

R¹⁶ is H, alkyl, haloalkyl, cycloalkyl or halocycloalkyl;

or R⁶ and R¹⁶ together with the carbon atoms to which they are attached form a double bond;

R¹⁷ is H, halogen, alkyl, haloalkyl, cycloalkyl or halocycloalkyl;

10 R¹⁸ ~~is cycloalkyl, alkylcycloalkyl, halocycloalkyl, alkylcycloalkylalkyl,~~
~~halocycloalkylalkyl, cycloalkylalkyl, cycloalkoxyalkyl, cycloalkylalkoxyalkyl,~~
~~triazolylalkyl, tetrazolylalkyl, aminoalkyl, substituted aminoalkyl, substituted aryl,~~
~~substituted heterocycloalkyl and substituted heteroaryl, wherein substituted~~
~~aminoalkyl is substituted on the nitrogen atom with one to two substituents~~
15 ~~independently selected from alkyl, cycloalkyl, alkylcycloalkyl, cycloalkylalkyl,~~
~~alkylcycloalkylalkyl, hydroxyalkyl and alkoxyalkyl, and wherein substituted aryl,~~
~~substituted heterocycloalkyl and substituted heteroaryl are substituted with R²⁸, R²⁹~~
~~and R³⁰;~~

20 R¹⁹ ~~is H, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl or~~
~~hydroxyalkyl;~~

or R¹⁸ and R¹⁹ together with the nitrogen atom to which they are attached form a
substituted heterocycloalkyl or a substituted heteroaryl, wherein substituted
heterocycloalkyl and substituted heteroaryl are substituted with R²⁸, R²⁹ and R³⁰;

R²⁰ is H, alkyl, haloalkyl, cycloalkyl or halocycloalkyl;

25 R²¹ is H, alkyl, haloalkyl, cycloalkyl or halocycloalkyl;

R^{22} is H, alkyl, haloalkyl, cycloalkyl or haloalkyl;

R^{23} is H, alkyl, haloalkyl, cycloalkyl or haloalkyl;

or R^{22} and R^{23} together with the carbon atom to which they are attached form a cycloalkyl;

R^{24} is H, alkyl, haloalkyl, cycloalkyl or haloalkyl;

5 R^{25} is H, alkyl, haloalkyl, cycloalkyl or haloalkyl;

or R^{24} and R^{25} together form $-(CH_2)_t-$;

R^{26} is H, alkyl, haloalkyl, cycloalkyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl or hydroxyalkyl;

10 R^{27} is H, alkyl, haloalkyl, cycloalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl, phenylalkyl, substituted phenylalkyl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, substituted heteroaryl, $-S(O)_2R^{31}$, $-S(O)_2OR^{31}$, $-S(O)_2NR^{31}R^{32}$, $-C(O)R^{31}$, or $-C(O)OR^{31}$ or $-C(O)NR^{31}R^{32}$, wherein substituted phenylalkyl, substituted aryl, substituted heterocycloalkyl and substituted heteroaryl are substituted with R^{28} , R^{29} and R^{30} , wherein in case R^{26} is H or alkyl and
15 R^{27} is H or alkyl, then the sum of q, r and p is at least 1;

or R^{26} and R^{27} together with the nitrogen atom to which they are attached form a substituted heterocycloalkyl or a substituted heteroaryl, wherein substituted heterocycloalkyl and substituted heteroaryl are substituted with R^{28} , R^{29} and R^{30} ;

20 or R^{25} and R^{26} together with the nitrogen atom to which they are attached form a substituted heterocycloalkyl or a substituted heteroaryl, wherein substituted heterocycloalkyl and substituted heteroaryl are substituted with R^{28} , R^{29} and R^{30} ;

or R^{23} and R^{26} together with the nitrogen atom to which they are attached form a substituted heterocycloalkyl or a substituted heteroaryl, wherein substituted heterocycloalkyl and substituted heteroaryl are substituted with R^{28} , R^{29} and R^{30} ;

25

or R^{21} and R^{26} together with the nitrogen atom to which they are attached form a substituted heterocycloalkyl or a substituted heteroaryl, wherein substituted heterocycloalkyl and substituted heteroaryl are substituted with R^{28} , R^{29} and R^{30} ;

R^{28} , R^{29} and R^{30} are each independently selected from H, alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, alkylcycloalkyl, halocycloalkyl, alkylcycloalkylalkyl, halocycloalkylalkyl, cycloalkylalkyl, cycloalkylalkoxy, cycloalkoxy, cycloalkoxyalkyl, cycloalkylalkoxyalkyl, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, alkoxyalkoxy, alkoxyalkoxyalkyl, alkoxycarbonyl, halogen, hydroxy, oxo, cyano, triazolylalkyl, tetrazolylalkyl, amino, substituted amino, aminoalkyl, substituted aminoalkyl, aminocarbonyl, substituted aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, alkylcarbonylaminoalkyl and cycloalkylcarbonylaminoalkyl, wherein substituted amino, substituted aminoalkyl and substituted aminocarbonyl are substituted on the nitrogen atom with one to two substituents independently selected from alkyl, cycloalkyl, alkylcycloalkyl, cycloalkylalkyl, alkylcycloalkylalkyl, hydroxyalkyl and alkoxyalkyl; wherein in case R^{14} is $S(O)_2R^{18}$ or in case R^{26} and R^{27} or R^{21} and R^{26} or R^{23} and R^{26} or R^{25} and R^{26} together with the nitrogen atom to which they are attached form a substituted heterocycloalkyl or a substituted heteroaryl, then at least one of R^{27} , R^{28} , R^{29} and R^{30} is different from H, alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, hydroxy, cyano, amino, substituted amino, aminocarbonyl or substituted aminocarbonyl, wherein substituted amino and substituted aminocarbonyl are substituted on the nitrogen atom with one to two alkyl;

R^{31} is H, C_1 - C_7 -alkyl, chloropyridinyl, hydroxyl- C_1 - C_7 -alkyl, haloalkyl, C_3 - C_8 -cycloalkyl, alkylcycloalkyl, halocycloalkyl, alkylcycloalkylalkyl, halocycloalkylalkyl, cycloalkylalkyl, cycloalkoxyalkyl, cycloalkylalkoxyalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxyalkoxyalkyl, triazolylalkyl, tetrazolylalkyl, aminoalkyl, substituted aminoalkyl, substituted aryl, substituted heterocycloalkyl and substituted heteroaryl, wherein substituted aminoalkyl is substituted on the nitrogen atom with one to two substituents independently selected from alkyl, cycloalkyl, alkylcycloalkyl, cycloalkylalkyl, alkylcycloalkylalkyl, hydroxyalkyl and alkoxyalkyl, and wherein substituted

~~—aryl, substituted heterocycloalkyl and substituted heteroaryl are substituted with R²⁸, R²⁹ and R³⁰;~~

~~R³² is H, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl or hydroxyalkyl;~~

5 n is zero, or 1 ~~or 2~~;

p is zero, or 1 ~~or 2~~;

q is zero, or 1 ~~or 2~~;

r is zero, or 1 ~~or 2~~;

~~t~~ is zero, 1, 2 or 3;

10 or pharmaceutically acceptable salts or esters.

~~2. — A compound according to claim 1, wherein R¹ is alkyl.~~

~~3. — A compound according to claim 1 or 2, wherein R² is H.~~

~~4. — A compound according to any one of claims 1 to 3, wherein R³ is H.~~

~~5. — A compound according to any one of claims 1 to 4, wherein R⁴ is H.~~

15 ~~6. — A compound according to any one of claims 1 to 5, wherein R⁵ is H.~~

~~7. — A compound according to any one of claims 1 to 6, wherein R⁶ is H, halogen or alkyl.~~

~~82. A compound according to any one of claims 1 to 7, wherein R⁶ is H.~~

~~9. — A compound according to any one of claims 1 to 8, wherein R¹² is H or halogen.~~

~~103. A compound according to any one of claims 1 to 92, wherein R¹² is H.~~

20 ~~11. — A compound according to any one of claims 1 to 10, wherein A¹ is CR¹³;~~

~~124. A compound according to any one of claims 1 to 113, wherein A² is CR¹⁵R¹⁶.~~

13. ~~A compound according to any one of claims 1 to 12, wherein A^{31} is CR^{17} .~~
14. ~~A compound according to any one of claims 1 to 13, wherein R^{13} is H or halogen.~~
15. ~~A compound according to any one of claims 1 to 12, wherein R^{16} is H, alkyl, haloalkyl, cycloalkyl or halocycloalkyl;~~
- 5 16. ~~A compound according to any one of claims 1 to 15, wherein R^{26} is H, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl or hydroxyalkyl.~~
17. ~~A compound according to any one of claims 1 to 16, wherein R^{26} is H.~~
18. ~~A compound according to any one of claims 1 to 17, wherein R^{27} is H, $S(O)_2R^{31}$, $C(O)R^{31}$ or $C(O)OR^{31}$, wherein in case R^{26} is H or alkyl and R^{27} is H, then the sum of q, r and p is at least 1.~~
- 10 19. ~~A compound according to any one of claims 1 to 18, wherein R^{27} is $S(O)_2R^{31}$ or $C(O)R^{31}$.~~
205. ~~A compound according to any one of claims 1 to 194, wherein R^{27} is $-C(O)R^{31}$.~~
21. ~~A compound according to any one of claims 1 to 20, wherein R^{31} is alkyl or chloropyridinyl.~~
- 15 226. A compound according to any one of claims 1 to 215, wherein R^{31} is C_1-C_7 alkyl.
23. ~~A compound according to any one of claims 1 to 22, wherein n is zero or 1.~~
247. A compound according to any one of claims 1 to 236, wherein n is 1.
258. A compound according to any one of claims 1 to 247, wherein q, r and p are zero.
269. A compound according to any one of claims 1 to 258, selected from
- 20 (rac)-N-[4-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-5,6,7,8-tetrahydro-isoquinolin-8-yl]-propionamide;
- (-)-N-(4-(1-Methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide ;

(rac)-N-(4-(1-Methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-6,7-dihydro-5H-cyclopenta[c]pyridin-7-yl)ethanesulfonamide;

{2-[5-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-3,4-dihydro-2H-[1,7]naphthyridin-1-yl]-ethyl}-carbamic acid tert-butyl ester;

5 6-[1-(2-Amino-ethyl)-1,2,3,4-tetrahydro-[1,7]naphthyridin-5-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one hydrochloride;

N-{2-[5-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-3,4-dihydro-2H-[1,7]naphthyridin-1-yl]-ethyl}-propionamide;

10 N-(2-(5-(1-Methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-3,4-dihydro-1,7-naphthyridin-1(2H)-yl)ethyl)ethanesulfonamide;

and pharmaceutically acceptable salts thereof.

~~27~~10. A compound according to any one of claims 1 to ~~25~~8, selected from

(2R,S)-2-Hydroxy-N-((4R,S)-4-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propanamide;

15 (2R)-2-Hydroxy-N-((4R,S)-4-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propanamide;

(2S)-2-Hydroxy-N-((4R,S)-4-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propanamide ;

20 (+)-(2R)-2-Hydroxy-N-((4R or 4S)-4-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propanamide;

(-)-(2R)-2-Hydroxy-N-((4S or 4R)-4-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propanamide;

(-)-(2S)-2-Hydroxy-N-((4S or 4R)-4-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propanamide;

25

(+)-(R or S)-N-(4-(8-Chloro-1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-6,7-dihydro-5H-cyclopenta[c]pyridin-7-yl)propionamide ;

(R)-6-(8-Amino-5,6,7,8-tetrahydroisoquinolin-4-yl)-1-methyl-3,4-dihydroquinolin-2(1H)-one;

5 3-Chloro-pyridine-2-carboxylic acid [(R)-4-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-5,6,7,8-tetrahydro-isoquinolin-8-yl]-amide;

N-[(R)-4-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-5,6,7,8-tetrahydro-isoquinolin-8-yl]-acetamide;

10 Cyclopropanecarboxylic acid [(R)-4-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-5,6,7,8-tetrahydro-isoquinolin-8-yl]-amide;

N-[(R)-4-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-5,6,7,8-tetrahydro-isoquinolin-8-yl]-methanesulfonamide ;

Cyclopropanesulfonic acid [(R)-4-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-5,6,7,8-tetrahydro-isoquinolin-8-yl]-amide ;

15 ~~(rac)-6-(8-Hydroxy-5,6,7,8-tetrahydro-isoquinolin-4-yl)-1-methyl-3,4-dihydroquinolin-2(1H)-one ;~~

~~(S or R)-6-(8-Hydroxy-5,6,7,8-tetrahydro-isoquinolin-4-yl)-1-methyl-3,4-dihydroquinolin-2(1H)-one ;~~

20 ~~(R or S)-6-(8-Hydroxy-5,6,7,8-tetrahydro-isoquinolin-4-yl)-1-methyl-3,4-dihydroquinolin-2(1H)-one ;~~

~~1-Methyl-6-(8-oxo-5,6,7,8-tetrahydro-isoquinolin-4-yl)-3,4-dihydro-1H-quinolin-2-one;~~

~~-N-[4-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-5,6-dihydro-isoquinolin-8-yl]-propionamide ;~~

25 (+)-(R)-N-(4-(1-Methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide;

and pharmaceutically acceptable salts thereof.

2811. A compound according to any one of claims 1 to 269, selected from

(+)-N-(4-(1-Methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide;

5 (+)-N-(4-(1-Methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)ethanesulfonamide;

(+)-N-(4-(1-Methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-6,7-dihydro-5H-cyclopenta[c]pyridin-7-yl)propionamide;

10 (rac)-N-(4-(1-Methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-6,7-dihydro-5H-cyclopenta[c]pyridin-7-yl)ethanesulfonamide;

N-{2-[5-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-3,4-dihydro-2H-[1,7]naphthyridin-1-yl]-ethyl}-propionamide;

and pharmaceutically acceptable salts thereof.

2912. A compound according to any one of claims 1 to 258 and 2710, selected from

15 (+)-(R or S)-N-(4-(7-Fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-6,7-dihydro-5H-cyclopenta[c]pyridin-7-yl)propionamide;

(+)-(R or S)-N-(4-(7-Fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-6,7-dihydro-5H-cyclopenta[c]pyridin-7-yl)ethanesulfonamide;

20 (+)-(R or S)-N-[4-(7-Fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-5,6,7,8-tetrahydro-isoquinolin-8-yl]-propionamide;

(+)-N-[(R or S)-4-(8-Chloro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-5,6,7,8-tetrahydro-isoquinolin-8-yl]-propionamide;

(+)-N-[(7S,8R or 7R,8S)-7-Methyl-4-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-5,6,7,8-tetrahydro-isoquinolin-8-yl]-propionamide;

(+)-N-[(7R,8R or 7S,8S)-4-(7-Fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-7-methyl-5,6,7,8-tetrahydro-isoquinolin-8-yl]-propionamide;

(+)-N-[(7S,8S or 7R,8R)-7-Fluoro-4-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-5,6,7,8-tetrahydro-isoquinolin-8-yl]-propionamide;

5 (+)-(R or S)-N-(4-(8-Chloro-1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-6,7-dihydro-5H-cyclopenta[c]pyridin-7-yl)propionamide ;

3-Chloro-pyridine-2-carboxylic acid [(R)-4-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-5,6,7,8-tetrahydro-isoquinolin-8-yl]-amide;

10 N-[(R)-4-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-5,6,7,8-tetrahydro-isoquinolin-8-yl]-acetamide;

(+)-(R)-N-(4-(1-Methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide;and pharmaceutically acceptable salts thereof.

3013. A compound according to any one of claims 1 to 2712, wherein the compound is (+)-(S or R)-N-(4-(1-Methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide or pharmaceutically acceptable salts thereof.

3114. A compound according to any one of claims 1 to 258, 2710 and 2912, wherein the compound is (+)-(R)-N-(4-(1-Methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide or pharmaceutically acceptable salts thereof.

15. A compound according to any one of claims 1 to 8, selected from


20 (rac)-6-(8-Hydroxy-5,6,7,8-tetrahydro-isoquinolin-4-yl)-1-methyl-3,4-dihydroquinolin-2(1H)-one ;

(S or R)-6-(8-Hydroxy-5,6,7,8-tetrahydro-isoquinolin-4-yl)-1-methyl-3,4-dihydroquinolin-2(1H)-one ;

25 (R or S)-6-(8-Hydroxy-5,6,7,8-tetrahydro-isoquinolin-4-yl)-1-methyl-3,4-dihydroquinolin-2(1H)-one ;

1-Methyl-6-(8-oxo-5,6,7,8-tetrahydro-isoquinolin-4-yl)-3,4-dihydro-1H-quinolin-2-one;
and pharmaceutically acceptable salts thereof.

~~32. A process to prepare a compound according to any one of claims 1 to 31 comprising the reaction of a compound of formula (II) in the presence of a compound of formula (III);~~



wherein $A^1, A^2, A^3, R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}$ and n are as defined in claim 1 and wherein X is halogen or triflate, R^{101} and R^{102} are alkyl, cycloalkyl or together with the boron atom they are attached to form together a borolanyl.

- 5 ~~3316.~~ A compound according to any one of claims 1 to ~~31~~15 for use as therapeutically active substance.

- ~~3417.~~ A compound according to claim ~~3316~~, wherein said compound is (+)-(R)-N-(4-(1-Methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide or pharmaceutically acceptable salts thereof.

- 10 ~~3518.~~ A pharmaceutical composition comprising a compound according to any one of claims 1 to ~~31~~15 and a therapeutically inert carrier.

- ~~3619.~~ A pharmaceutical composition according to claim ~~3518~~, wherein said compound is (+)-(R)-N-(4-(1-Methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide or pharmaceutically acceptable salts thereof.

- 15 ~~37.~~ The use of a compound according to any one of claims 1 to ~~31~~ for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome.

- ~~38.~~ The use of a compound according to any one of claims 1 to ~~31~~ for the treatment or prophylaxis of diabetic nephropathy.

39. ~~The use of a compound according to any one of claims 1 to 31 for the treatment or prophylaxis of kidney or heart fibrosis.~~

40. ~~The use according any one of claims 37 to 39, wherein said compound is (+) (R)-N-(4-(1-Methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide or pharmaceutically acceptable salts thereof.~~

41~~20~~. A compound according to any one of claims 1 to 31~~15~~ for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome.

42. ~~A compound according to any one of claims 1 to 31 for the treatment or prophylaxis of diabetic nephropathy.~~

43. ~~A compound according to any one of claims 1 to 31 for the treatment or prophylaxis of kidney or heart fibrosis.~~

44~~21~~. A compound according to any one of claims 41 to 43~~20~~, wherein said compound is (+)-(R)-N-(4-(1-Methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide or pharmaceutically acceptable salts thereof.

45. ~~The use of a compound according to any one of claims 1 to 31 for the preparation of a medicament for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome.~~

46 ~~The use of a compound according to any one of claims 1 to 31 for the treatment or prophylaxis of diabetic nephropathy.~~

47 ~~The use of a compound according to any one of claims 1 to 31 for the treatment or prophylaxis of kidney or heart fibrosis.~~

48. ~~The use according to any one of claims 45 to 47, wherein said compound is (+) (R)-N-(4-(1-Methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide or pharmaceutically acceptable salts thereof.~~

~~49. A method for the treatment or prophylaxis chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome, which method comprises administering an effective amount of a compound according to any one of claims 1 to 31.~~

5 ~~50. A method for the treatment or prophylaxis of diabetic nephropathy, which method comprises administering an effective amount of a compound according to any one of claims 1 to 31.~~

~~51. A method for the treatment or prophylaxis of kidney or heart fibrosis, which method comprises administering an effective amount of a compound according to any one of claims 1 to 31.~~

10 ~~52. A method according to any one of claims 49 to 51, wherein said compound is (+)-(R)-N-(4 (1 Methyl 2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide or pharmaceutically acceptable salts thereof.~~

~~53. A compound according to any one of claims 1 to 31, when manufactured according to a process of claim 32.~~